This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (54)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

J. Donald M. Gass, MD

Arch Ophthalmol. 1985;103(7):916-923.

Abstract
• Between December 1962 and May 1979, growth of choroidal and ciliary body melanomas was documented in 34 patients prior to enucleation. Twenty-seven of the 34 patients underwent enucleation during the same time period (1967 through 1976), when primary treatment with a cobalt 60 episcleral plaque was employed in a nonrandomized fashion in 21 patients with similar-sized melanomas. Comparison of these two groups of patients, none of whom was unavailable for follow-up and all of whom were followed up for a minimum of 66 months, showed that the probability of dying of metastatic melanoma within five years after cobalt 60 therapy was 50% compared with 16% after enucleation. Factors of potential importance in explaining this difference included (1) nonrandomization, (2) small number of patients in both groups, and (3) greater frequency of anterior location of tumors in the cobalt 60 group (76% vs 22%). A randomized, controlled clinical trial is required to determine the relative safety of treatment for uveal melanomas.

Author Affiliations
From the Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami School of Medicine.

Footnotes
Accepted for publication Feb 4, 1985.

Presented as the 45th George E. de Schweinitz Lecture at the Section on Ophthalmology meeting of the College of Physicians of Philadelphia, Philadelphia, Nov 18, 1982.

Reprints not available.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Investigators' Perspective on the Collaborative Ocular Melanoma Study
Fine and Hawkins
Arch Ophthalmol 2007;125:968-971.
FULL TEXT  

Assessment of Metastatic Disease Status at Death in 435 Patients With Large Choroidal Melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS Report No. 15
The Collaborative Ocular Melanoma Study Group
Arch Ophthalmol 2001;119:670-676.
ABSTRACT | FULL TEXT  

Treatment Choice and Quality of Life in Patients With Choroidal Melanoma
Cruickshanks et al.
Arch Ophthalmol 1999;117:461-467.
ABSTRACT | FULL TEXT  

A Review of Mortality From Choroidal Melanoma: II. A Meta-Analysis of 5-Year Mortality Rates Following Enucleation, 1966 Through 1988
Diener-West et al.
Arch Ophthalmol 1992;110:245-250.
ABSTRACT  

Cox Regression Analysis in Clinical Research
Seigel
Arch Ophthalmol 1990;108:888-889.
ABSTRACT  

Enucleation vs Cobalt Plaque Radiotherapy for Malignant Melanomas of the Choroid and Ciliary Body
Augsburger et al.
Arch Ophthalmol 1986;104:655-661.
ABSTRACT  

Enucleation vs Cobalt 60 Irradiation of Melanomas
Seddon et al.
Arch Ophthalmol 1986;104:175-176.
ABSTRACT  

Ocular Melanoma
Gamel
Arch Ophthalmol 1985;103:1284-1284.
ABSTRACT  

How Should We Manage a Patient With Uveal Melanoma?
Fine
Arch Ophthalmol 1985;103:910-911.
ABSTRACT